(Q64173166)
Statements
Open-label, Single-center, Single-arm Futility Trial Evaluating Oral Hydroxychloroquine 200mg BID for Reducing Progression of Disability in Patients With Primary Progressive Multiple Sclerosis (PPMS) (English)
0 references
November 2016
0 references
October 2020
0 references
35
0 references
18 year
0 references
65 year
0 references